UK markets close in 1 hour 49 minutes

Neurocrine Biosciences, Inc. (0K6R.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
73.28-1.34 (-1.80%)
As of 06:49PM GMT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) N/A
Enterprise value N/A
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 0.73
52-week change 3N/A
S&P500 52-week change 314.56%
52-week high 375.21
52-week low 372.97
50-day moving average 3N/A
200-day moving average 3N/A

Share statistics

Avg vol (3-month) 3N/A
Avg vol (10-day) 3N/A
Shares outstanding 590.68M
Implied shares outstanding 6N/A
Float 893.62M
% held by insiders 11.42%
% held by institutions 197.43%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 4N/A
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2020
Most-recent quarter (mrq)30 Sept 2021

Profitability

Profit margin 41.59%
Operating margin (ttm)20.16%

Management effectiveness

Return on assets (ttm)7.66%
Return on equity (ttm)41.37%

Income statement

Revenue (ttm)1.07B
Revenue per share (ttm)11.35
Quarterly revenue growth (yoy)14.50%
Gross profit (ttm)760.8M
EBITDA 225.7M
Net income avi to common (ttm)444.8M
Diluted EPS (ttm)4.54
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)765.9M
Total cash per share (mrq)8.07
Total debt (mrq)452.6M
Total debt/equity (mrq)33.63
Current ratio (mrq)4.45
Book value per share (mrq)14.20

Cash flow statement

Operating cash flow (ttm)346.8M
Levered free cash flow (ttm)253.18M